November 19, 2024
On November 19, 2024, REGENXBIO Inc. shared a letter to the Duchenne community sharing an update on RGX-202, REGENXBIO’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.
To view their community letter, please click here.
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
